SCHEMBL5052306

SCHEMBL5052306

CNc1ncc2cc(-c3ccc(F)c(NC(=O)Nc4cc(C(C)(C)C)nn4-c4ccc5ocnc5c4)c3)c(=O)n(C)c2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 12/20 0.45
RAF1 P04049 5/20 0.45
MAPK14 Q16539 6/20 0.43
MAPK12 P53778 3/20 0.43
MAPK11 Q15759 3/20 0.43
MAPK13 O15264 2/20 0.43
KDR P35968 4/20 0.43
KRAS P01116 3/20 0.43
MAP2K2 P36507 2/20 0.43
MAP2K1 Q02750 2/20 0.43
PTK2 Q05397 2/20 0.39
ABL1 P00519 2/20 0.39
DDR2 Q16832 3/20 0.38
PLK4 O00444 1/20 0.37
ACOX3 O15254 1/20 0.37
MAP3K7 O43318 1/20 0.37
DYRK3 O43781 1/20 0.37
JAK2 O60674 1/20 0.37
ERN1 O75460 1/20 0.37
RPS6KA4 O75676 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5055164 0.90 BRAF (0.45) BRAFRAF1MAPK14MAPK12MAPK11
SCHEMBL5060109 0.89 MAPK14 (0.50) BRAFRAF1MAPK14MAPK12MAPK11
SCHEMBL5055144 0.88 BRAF (0.45) BRAFRAF1MAPK14MAPK12MAPK11
SCHEMBL4425259 0.88 MAPK14 (0.52) BRAFRAF1MAPK14MAPK12MAPK11
SCHEMBL4427768 0.87 BRAF (0.49) BRAFRAF1MAPK14MAPK12MAPK11
SCHEMBL5055112 0.87 MAPK14 (0.53) BRAFRAF1MAPK14MAPK12MAPK11
SCHEMBL5052173 0.87 ABL1 (0.47) BRAFRAF1MAPK14MAPK12MAPK11
SCHEMBL5060539 0.87 ABL1 (0.55) BRAFRAF1MAPK14MAPK12MAPK11
SCHEMBL5052387 0.87 BRAF (0.47) BRAFRAF1MAPK14MAPK12MAPK11
SCHEMBL5052284 0.86 MAPK14 (0.47) BRAFRAF1MAPK14MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 BRAF 2/4885RAF1 55/4885MAPK14 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.